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Abstract
Anesthesia care is delivered world wide on a daily basis. Provision of anesthesia cares for
surgical, obstetrical, or pain management procedures mandate a thorough understanding of
physiology, pathophysiology, and pharmacology. Nearly 4 million anesthetics are delivered in
the United States each year and the impact of genetics on anesthesia care is becoming greater.
Anesthesia providers make prescriptive decisions based on an individual patient’s disease
processes, proposed surgical or therapeutic procedure, and a thorough clinical history. The age
of personalized medicine is upon us and the ability to use genetic testing to help predict how a
patient will respond to various medications is here. By using genetically coded single nucleotide
polymorphism programming of the metabolic pathways in the liver, drugs responsiveness can be
more precisely predicted and explained. This dissertation focuses on the clinical utility of
genetic testing to predict drug responsiveness (pharmacogenomics) among anesthesia providers
with a focus on treating acute pain. Specifically, the following research question is addressed:
What is the clinical utility of pharmacogenomic testing to support prescriptive decision making
among anesthesia providers. To answer this research question, a mixed-method sequential
qualitative quantitative study was carried out. The conclusions of this research are (a) anesthesia
providers lack knowledge concerning pharmacogenomic testing, (b) anesthesia providers are
concerned about potential ethical and economic issues surrounding genetic testing, and (c)
anesthesia providers perceive a potential benefit to using pharmacogenomic testing as it relates
to making prescriptive decisions. Further work is necessary to more carefully refine the
instrument used to measure clinical utility as well as future intervention work aimed at increasing
anesthesia provider knowledge about pharmacogenomic testing.
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Chapter 1: Introduction
Knowledge in the Field of Study
Pharmacogenomic testing is becoming more widely used to help make
personalized healthcare decisions, however, a stark gap exists in the literature about the
perceived clinical utility of pharmacogenomic testing in supporting prescriptive decisionmaking in anesthesia practice. The majority of anesthetic pharmacogenomic testing lies
focuses on the cytochrome P450 (CYP450) enzyme system that metabolize medications.1
CYP450 enzymes are found primarily in the liver and their activity level is in some part
responsible for how a patient will respond to a medication.2-4 Although there is
heterogeneity among patients current estimations purport 60 CYP450 pathways;
replicated studies have shown six of these are responsible for 90% of all metabolism of
all available medications.1
Each individual possesses a different CYP450 system that results in varied
responses to medication between people.1 Pharmacogenomic testing can help categorize
how an individual’s variation in genetic penetrance and expressivity will control for
CYP450-mediated drug metabolism rates.5 Traditionally, prescriptive decisions for
medications are made mostly on a trial-and-error basis. These methods use sound science
by combining what is individually known about a patient’s physiology and
pathophysiology so they are somewhat patient specific.1 Unfortunately, this approach to
making prescriptive decisions is not completely objective or accurate and the incidence of
adverse drug events, unnecessary risk exposure, and elevating costs mandate the need to
use better methods to inform clinical prescriptive decisions.
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Current Practice
In the area of pain management, the administration of opioid analgesics to help
control acute pain in the perioperative period is the mainstay of practice. It is well
established that opioid analgesics carry significant risk even when administered at
normally accepted doses.6,7 The risks associated with opioid analgesics include
respiratory depression, respiratory arrest, and even death. Additionally, the side effect
profile of opioid analgesics is profound and can include pruritis, nausea, vomiting,
constipation, urinary retention, and somnolence and can impact patient satisfaction and
adherence to prescribed therapy.5,8 Better and more patient-specific best practice methods
are warranted as needed as they can help to avoid these possible severe events and
diminish the more minor risks.
The ability to personalize care with pharmacogenomics is based on an
individual’s genetic profile (genotype) and the penetrance and expressivity of many
different single nucleotide polymorphisms (SNP) that influence the way the liver
metabolizes drugs through the CYP450 systems.2 The specific concern for opioid
analgesics is the CYP2D6/2C9 SNP that help control metabolism in a slow, fast, and
ultra-fast manner.2,3 Because the CYP2D6/2C9 SNP control for the metabolism of
opioids, testing and interpretation of these genotypes can help the anesthesia provider
better plan and dose opioids to achieve optimal analgesic effects without the burdensome
and dangerous side effects typically seen with inappropriate opioid selection and dosing.6
This will help to ensure the right drug is prescribed at the right dose in the right patient at
the right time. By avoiding excessive doses of potentially lethal opioid analgesics in
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patients with genotype-specific programmed slow opioid metabolism, adverse drug
events can be avoided.6

Figure 1. Four potential outcomes of medication administration
Pharmacogenomic Testing
There are many commercially available, low cost pharmacogenomic tests
available to practitioners to help inform prescriptive decision-making regarding
medications.1 These tests include in-office testing for very specific SNPs or larger assays
that will help practitioners determine patient response to a large variety of medications.
Outcome studies demonstrate superior patient responses and decreased side effect
profiles when pharmacogenomic testing is used by practitioners to help understand
clinical prescriptive decisions; however, uptake by the healthcare community remains
extremely low.2,6,7,9-14 The perceived clinical utility of pharmacogenomic testing,
specifically among anesthesia providers, is unknown. A gap exists in the literature
pervades regarding how anesthesia providers perceive clinical utility of
pharmacogenomic testing.
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Clinical Utility
For a test, treatment, or technology to be considered useful it must be
demonstrated that it has clinical utility.15 To date, data exists of the perceived clinical
utility of pharmacogenomic testing among healthcare providers as a whole and among
family practice physicians, however, no studies exist demonstrating clinical utility of
pharmacogenomic testing among anesthesia providers.15,16 5,13,14,17-19 The feasibility of
conducting clinical utility perception studies has been well-established, however, there
are no data to demonstrate the knowledge, education, perceived benefits and barriers, and
perception of pharmacogenomic testing use to inform prescriptive decision-making
among anesthesia providers in the United States.
Pharmacogenomic Testing in Anesthesia
The purpose of manuscript one was to exploration of the concept of genetic
predisposition as it related to healthcare decision-making.20 An exhaustive literature
review to explore the concept of genetic predisposition with the understanding that the
concept of genetic predisposition is the underpinning science behind pharmacogenomic
testing was conducted. It was discovered that the concept of genetic predisposition is
immature overall but does have some degree of pragmatic maturity.20 Based on this
analysis, the concept of genetic predisposition can be defined as the use of genetic testing
to predict disease, stratify risk, identify susceptibility and guide prevention of disease.20
The purpose of manuscript two was to complete an integrative review of the
instruments currently used to measure acute pain. In order to measure a concept, in this
case a physiologic concept of pain, an instrument with sound psychometrics is necessary.
In order for an anesthesia provider to understand the effectiveness of an intervention
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aimed at treating (or reducing) pain levels, appropriate instruments with sound
psychometric measurements are necessary. In this review, it was determined that most
clinically-used instruments to measure acute pain are not psychometrically solid,
however, there are five instruments currently available that have moderate psychometric
properties rendering them clinically useful for acute pain measurement.21
Despite an understanding of the concept of genetic predisposition and known
psychometrically-sound instruments that can be used to measure acute pain, no data
exists on the perceived clinical utility of pharmacogenomic testing among anesthesia
providers. There are also no instruments that measure clinical utility of
pharmacogenomic testing among anesthesia providers. The purpose of manuscript three
of this dissertation, therefore, is to report on the results of a mixed-method study that
aimed at describing the perceived clinical utility of pharmacogenomic testing among
currently practicing anesthesia providers. Additionally, this manuscript reports on the
fundamental psychometric testing of a yet-to-be developed future instrument aimed at
measuring the degree of clinical utility of pharmacogenomic testing among anesthesia
providers.
Theoretical Framework
The framework guiding this dissertation was the Centers for Disease Control and
Prevention’s (CDC) ACCE Model of Public Genomics.22 In this model, the CDC has
proposed a conceptual model for comprehensive evaluation of clinical utility of various
types of genetic testing. The model’s dimensions include analytic validity, clinical
validity, clinical utility, and ethical, legal, and social implication of a genetic test. The
specific portion of the model used in this dissertation is the outer ring of clinical utility.
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Figure 2. ACCE Model of Public Genomics
Collectively, the three manuscripts of this dissertation describe the clinical utility
of a genetic test. The specific genetic test is pharmacogenomic testing as it relates to
helping anesthesia providers make decisions about opioid analgesics to treat acute pain.
Guided by the CDC ACCE Model of Public Genomics, this body of work seeks to
answer the research question: What is the perceived clinical utility of pharmacogenomic
testing among anesthesia providers?
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Chapter 2: Genetic disposition: A principle-based concept analysis
Riddle, D. (2014). Published in the International Public Health Journal, 6(1) 23-32.20
Abstract
Aim. To report an analysis of the concept of genetic predisposition.
Background. The discipline of genetics has evolved tremendously in the past few
decades. The impact of genetics on nursing practice and research is burgeoning and the
concept of genetic predisposition is emerging in the literature.
Design. Concept analysis
Data sources. A total of seventeen articles in the English language are used.
Method. The principle-based concept analysis method was used to analyze the concept
of genetic predisposition.
Results. Genetic predisposition has overall conceptual immaturity. The epistemological,
linguistic, and logical principles all show mild to moderate maturity as related to genetic
predisposition. The concept has pragmatic maturity with the caveat that the contextual
placement of the concept be understood.
Conclusion. A definition of the concept of genetic predisposition is suggested as well as
a direction for future research.

Keywords. Concept analysis, genetic predisposition, principle-based, nurse, nursing,
genetics
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Genetic Predisposition: A Principle-Based Concept Analysis
Within the profession of nursing, the incorporation of genetics into caring for
patients has become almost commonplace in the past several years. The use of genetics
includes diagnostics, screening, and helps inform clinical treatment decisions.23 Within
the emerging field of genetics, there lie several concepts that are frequently encountered
such as genetic relevance, genomics, pharmacogenomics, and genetic testing. The goal
of this paper is to add clarity to the concept of genetic predisposition through a formal
concept analysis using the Principle Based Concept Analysis method. This method is
chosen because it helps explain the current state of the science related to a concept and is
useful when the concept is relatively immature.24
Concept Definition
Genetic predisposition is the combination of the terms ‘genetics’ and
‘predisposition’, each of which could be individually considered concepts but the
combination of the two words leads to a third unique concept. Using many sources, this
section aims to first define genetics and predisposition independently. After the
independent definitions are examined, the concept of genetic predisposition as a whole
will be explored.
Genetics, as defined by the Oxford English Dictionary (OED),25 is the “scientific
study of inherited variation in living organisms, and the cellular and molecular processes
responsible for this.” Furthermore, the OED specifies that the branch of biology
concerned with studying inherited variation be called genetics. Historically, the term
genetics first appeared in 1905 when scientists were trying to describe the study of
heredity and the term genetics was agreed upon as the best definition. The scientific
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community agreed that the term gene would be used to describe the basic unit of heredity
with genetics being the study of heredity. In 1968, the New England Journal of Medicine
first published a scientific paper about the genetics of alpha1-antritypsin deficiency and
used the term genetics to describe the cause of this protein deficiency.25
Predisposition is a term defined as the pre-existing tendency to suffer from a
disease of medical condition.26 Its use dates back to 1622 when Henry VII was described
as having the “sweating sickness” as a result of the predisposition of the seasons. Later
in 1707, physicians began using the term predisposition to describe a patient’s likelihood
of contracting a disease based on their family history of a similar disease. In this
century, the term predisposition has been used to describe someone who is presymptomatic for a disease but has not yet demonstrated clinical signs for the particular
disease.26 An example of this is a person who has a family history of diabetes but has yet
to have elevated blood glucose levels.27
In order to define genetic predisposition, the combination of genetics and
predisposition must be used. For the purposes of this submission, combining these words
gives genetic predisposition the following meaning: a preexisting tendency to suffer a
disease or medical condition based upon inherited variations of living organisms. Stated
another way, genetic predisposition is the likelihood of having a disease or medical
condition as determined by specific cellular or molecular markers that have been
inherited.
Other Definitions
The concept of genetic predisposition is widely used in scientific literature
regarding the study of genetics. In the arena of primary genetic research, scientists use
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the term genetic predisposition to describe the molecular and cellular markers of
disease.28 In this context, genetic predisposition has no human element but rather the
results of a genetic testing profile that is paired with a disease process. Thus, there is no
particular relationship between a test result and a patient; it is simply an example of
statistics indicating result X will mean disease Y has a high probability of occurring.28 In
this realm, genetic predisposition could be considered a cold, isolated concept.
Elsewhere, when the term genetic predisposition is used, scientists are referring to
a particular patient or set of patients. There are known genetic tests that will yield results
related to specific diseases. The concept of genetic predisposition, in this case, is used to
describe those patients at risk for developing the disease in question.29 In this light,
genetic predisposition is a proposition of what might happen or what could happen based
on genetic profiling.30 One example of a disease is epilepsy and the various genetic tests
for the disease. Emerging as a central focus of epilepsy research, genetic testing has
identified more than 20 genes thought responsible for epilepsy.29 Patients possessing one
or more of these particular genes are considered to have a genetic predisposition for
development of epilepsy.
Another use of the concept of genetic predisposition is not found in the biological
science literature but rather in social science and theological literature. In this venue,
genetic predisposition is seen through the lens of vulnerability and the unknown.31 In
this light, the concept of genetic predisposition is highly correlated with risk; that is to
say genetic predisposition is inherently paired with a risk for disease and comorbidity.31
Using genetic testing to determine the risk of developing cancer highlights an example of
this use of genetic predisposition. There are many in the population that would not like
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to know this information and by receiving such testing for genetic markers of cancer
significant psychological harm may occur.31
A final use of genetic predisposition is centered on the idea of susceptibility or
vulnerability. In this context, genetic predisposition refers to the anticipated response to
a drug or treatment.28

An example of this would be the use of genetic testing to

determine a patients genetic predisposition to the effects of opioid pain medication.9 In
this context, genetic predisposition can help predict adverse or unwanted side effects of
medications. Testing can be performed to help inform clinical decision making to ensure
the best possible patient outcome.
Conceptual Framework
Genetic predisposition can be grounded in the Systems Biology Conceptual
Framework. Systems biology poses that science is derived from interdisciplinary study
of complex systems and then synthesized to investigate cellular-level biological
processes.32 This approach is holistic and involves specific applications to the study of
genes, their proteins for which they code, and the resulting phenotype. Specific to
genetics research, the Systems Biology Framework allows for a strategy to study diseases
with a genetic basis. Interdisciplinary teams of nurses, physicians, epidemiologists, and
biostatisticians can work together using one conceptual framework.32
In the Systems Biology Framework, the nurse scientist assumes that one
intervention can result in a dynamic process in multiple levels of the person such as the
genetic, molecular, cellular, and organ system level.32 In application to genetics, it is
Systems Biology Theory that says genetics could have an impact on disease initiation or
progression. An important aspect of Systems Biology Theory allows for the impact of
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environment and intervention to impact the resulting disease.32 Studies undertaken using
Systems Biology Theory help to understand the complex interaction of genes and their
impact on disease progression and treatment. A conceptual model of Systems Biology
Theory is listed below, Figure 1.
Figure 1. Systems Biology Conceptual Model

Literature Review
Structure of Search
A purposeful and exhaustive literature search is obligatory to increase rigor and
decrease bias in a concept analysis.33 A three-step search strategy was utilized in this
concept analysis. An initial limited search of MEDLINE and CINAHL was undertaken
followed by analysis of the text words contained in the title and abstract, and of the index
terms used to describe the article. This search was performed to identify historical views
of genetic predisposition. A second search using all identified keywords and index terms
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were undertaken across all included databases. Thirdly, the reference list of all identified
reports and articles was searched for additional studies.
Databases included in the exhaustive search included EBSCOhost (CINAHL,
MedLine, eBook Collection, and MasterFILE Premier), PubMed, Science Direct, and Pro
Quest. Libraries from two universities were utilized as well as the assistance of a
reference librarian to help define search terms and Boolean phrases appropriate to the
concept. The search was limited to articles in English language only as translation
services are not available. Additionally, only articles discussing human subjects were
included. There are numerous studies that speak to genetic predisposition in animal and
plant species as well. The timeframe for the search was 1950 through October 2012. All
articles were retrieved either electronically or through interlibrary loan services.
Search Results
The initial search was in the EBSCOhost database that includes CINAHL,
MedLine, eBook Collection and MasterFILE Premier search engines. Keywords used
included genetic predisposition, genetic AND predisposition, gene* predisposition, and
“genetic predisposition” in all data fields. The searches were limited to English language
and human subjects only. This search strategy resulted in a total of 722 articles.
The next search was in the ProQuest database. Keywords used were genetic
predisposition, “genetic predisposition”, and genetic AND predisposition. Again, the
language was limited to English and human subjects were only examined. This search
strategy results in 233 articles for consideration.
The final literature search was using Science Direct. The keywords included
genetic predisposition, “genetic predisposition”, and gene* predisposition. Limiting this
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search to English language only, a total of 110 articles were returned. After looking
closely at these articles, 20 were excluded in this initial search based on non-human
subjects. Therefore, Science Direct yielded 90 articles for the purposes of this concept
analysis.
A total of 1822 articles were retrieved using the outlined search strategy. An
initial review of the title allowed for exclusion of 1451 articles. The abstracts of the
remaining 371 articles were then read and considered. Studies includes in this analysis
must have distinctly discussed genetic predisposition and defined some aspect of the
meaning of this term. Many studies retrieved that mentioned genetic predisposition but
after careful analysis these studies did not speak comprehensively about this term.
Additional articles were excluded from analysis because they were editorial statements.
Included in the literature matrix are primary research studies and review articles speaking
directly to the concept of genetic predisposition. This process resulted in 17 articles for
analysis. The details for each article are presented in Table 1, below.
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Attribute
Predictive

Articles
15

34

31

	
  

Description of
Concept
-genetics can
forecast what
might happen
-predisposition is
seen as
development of
disease/condition
-well defined
genetic
events/mutations
can show
progression to
cancer
-predictability of
genetic mutations
in a particular
sequence
-prediction of
disease (focus on
cancer)
-prevention of
disease based on
results of testing
-genetic testing can
be seen like
mammogram and
pap smear – testing
for disease that’s
preventable if
treated

Measurement/Study
Design
-None, integrative
review article with
meta-analysis
calculations

Study
Purpose/Question
-Can genetic
biomarkers determine
drug-induced liver
injury?
-review article

-None, integrative
review article

-What are the defined
mechanisms involved
in genetic
predisposition to
development of
colorectal cancer?
-review article

-to test a model of
intentions based on
theory of reasoned
action
-n=1824 adults,
recruited from across
U.S.
-outcome was
behavioral intention
(intent to get genetic
testing)

-What is the influence
of religion on
decisions to undergo
genetic testing?
-4 hypotheses tested

Results

Critique

-genetics can help
predict liver injury
(often highly
predictable) but not
guarantee results

-review article
looking at 12 primary
research articles
-no detailed search
strategy noted

-step-wise
progression of gene
polymorphisms
predicts colorectal
cancer
-gene-environment
and gene-gene
interaction is highly
correlated with
cancer development
-religion affiliation
results in negative
feelings towards
genetic testing
-if question was
phrased as “disease
is completely
treatable and GT
can predispose you
to good treatment”
then high
correlation with
testing

-exhaustive literature
search
-well defined
inclusion/exclusion
criteria
-differentiated
between high and
low penetrance
genetic mutations
-interesting study
looking at religion,
previous experiences,
and question wording
on attitudes about
genetic testing
-not all hypotheses
were completely
clear or addressed in
discussion/conclusion

15	
  

	
  

Attribute

Articles
35

36

	
  

Description of
Concept
-likelihood of
development of
side-effects from
medication
-predictability of
drug performance
-seen as a positive
predictive factor

Measurement/Study
Design
-pilot study, n=109
-all morbidly obese
patients
-looked at 3 SNPs
associated with
morphine
metabolism
-wanted to define a
candidate gene
responsible for
morphine
pharmacodynamics

Study
Purpose/Question
-Is there a gene
implied in opioid
pharmacodynamics in
obese patients?

-forecasting of
disease
-filtering of genetic
information to
determine highest
prediction rate of
disease
-identification of
those with disease
earlier

-feasibility study,
n=50
-recruited patients
from the Familial
Breast Cancer Study
-prospective, cohort
study

-Explore feasibility of
using gene exome
sequencing technique
to predict breast
cancer rates

Results

Critique

-3 SNPs were found
among the group
-A118G was seen in
higher frequency in
obese population
compared to
general population
-presence of this
SNP may be
predictive of opioid
effectiveness and
possibility of sideeffects
-exome sequencing
is revolutionary in
identifying rare
genetic variants
-predisposition to
disease may be
better determined
by exome
sequencing
-feasible to use this
technique, exact
methods need
further investigation

-pilot study so results
are not generalizable
to entire population
or even all obese
patients
-very clear that
further testing on this
gene in obese
patients needs to be
conducted to
determine clinical
relevancy
-utility of this
technique is not fully
known
-spoke extensively of
prediction power of
genetic testing as the
predisposition to
disease
-results not
generalizable nor
clinically useful yet
until further
techniques are
developed

16	
  

	
  

Attribute

Articles

Description of
Concept
-prediction of
suicide is related to
genetic markers
-ability to help
determine who is
going to have
suicidal behavior

Measurement/Study
Design
-none, literature
review

Study
Purpose/Question
-Is there a genetic
predisposition to
suicide?

38

-incidence of
disease
development
-factors, including
genetics, contribute
to diagnosis

-n=17.035
-nested-case control
prospective cohort
study

-Is there an
association between
SNPs and breast
cancer – based on age
and parity?

39

-incidence of
disease
-determining the
patient at most risk
-assessment of
probability

-integrative review
article

-What is the current
state of the science
regarding genetic
predisposition to
malignant melanoma

37

Risk

	
  

Results
-high correlation
between genetics
and mood disorders
and suicide
-not enough
evidence to suggest
an association
between genetics
and suicide
-6 distinct SNPs do
put patients at
higher risk of
development of
breast cancer
-no association with
age or parity
-risk stratification
based on a
particular set of
high risk, medium
risk, and low risk
genetic markers

Critique
-excellent inclusion
of varying studies
-controlling for
extraneous variables
in inclusion criteria
gave strength to
conclusions
-huge sample size
-all women in
Sweden born
between 1923-1950
invited to participate
-results only
applicable to women
of northern European
origin?
-excellent review of
molecular risk
assessment strategies
-poorly described
literature review
process

17	
  

	
  

Attribute

Articles
29

30

	
  

Description of
Concept
-risk associated
with need for
further testing
-incorporation with
heredity and
environment
determines
absolute risk
-relative risk,
awareness

Measurement/Study
Design
-review article

Study
Purpose/Question
-What is the current
state of the science
regarding genetic
testing
(BRAC1/BRAC2)
and breast/ovarian
cancer

-disease
development is
inherently
bad/negative
-genetic testing can
show risk of
potential negative
outcomes
-genes do not
completely show
risk, interaction
with environment
and lifestyle are
needed

-None, integrative
review article

-What is the current
state of the science
regarding genes and
cardiac disease?

Results

Critique

-BRCA1/BRCA2
determine
molecular basis of
disease
-should not be used
for overall
population
screening
-results are a basis
for determining risk
estimation
-23 of 33 previously
thought of genetic
loci do not increase
risk of CAD
-CAD is propagated
by factors other
than pure genetics
-lifestyle and
environment play
big role in
development of
CAD
-predictive genetic
variants are not
ready for routine
testing

-great review of the
physiology of cancer
-excellent literature
review
-defined
predisposition and
risk well

-interesting insight
into the need to back
down from genetic
testing until the
science is more solid
-good explanation
about what was know
and why that is now
being dismissed
-discussed risk as
very negative and
decreasing risk as
very positive

18	
  

	
  

Attribute

Articles
16

31

	
  

Description of
Concept
-genetic testing
help stratify risk of
disease
-knowing results
can decrease
anxiety, though
risk is still present
-genetics and
environment
complete the risk
profile

Measurement/Study
Design
-Qualitative study
design
-n=40 in depth
interviews
-from previous
sample of epilepsy
study group at
Columbia University

-genetic makeup
can predict risk of
disease
-genetic makeup
can be protective in
some cases
-genetics can help
explain clinical
progression

-pilot study
-prospective, cohort
study
-n=93 patients
-all had ESRD
-regression analysis,
ANOVA, and
Pearson correlations
used

Study
Purpose/Question
-How do people with
epilepsy and their
family members
understand genetics?
-How do people with
epilepsy and their
family members
perceive risks and
benefits of genetic
testing?
-What do people’s
hope and fears
regarding genetic
testing reveal about
the local moral
worlds of people with
epilepsy?
-Pilot study to
determine an
association between
genetics, ESRD, and
depression
development

Results

Critique

-revealed people
want more
information about
ontology of
epilepsy
-universally
genetics is seen as
risk stratification
-most felt genetic
testing offered
benefits in
knowledge and
lifestyle issues
including
reproduction

-insightful study
examining people’s
understanding of
genetics as a whole
-theme of
reproduction
(heritability) emerged
which was seen as an
unexpected finding

-association
between certain
SNPs (AA variant)
and development of
depression
-seen as a risk (if
AA, then risk of
developing
depression is
higher)

-excellent study
design,
comprehensive
statistical analysis
-pilot study, limited
results

19	
  

	
  

Attribute

Articles
32

Susceptibility

	
  

33

Description of
Concept
-dyslipidemia is
associated with
DM-2
-genetic makeup
can show risk for
developing
dyslipidemia and
ultimately DM-2
-risk is based on
the genetic makeup

Measurement/Study
Design
-nested, cohort study
-n=5,499
-examined specific
lipid loci in study
and control patients
-examined more than
specific SNPs, tested
for gene-wide loci
for lipid production

Study
Purpose/Question
-Investigate the
association between
genetic predisposition
to dyslipidemia and
DM-2 development

-certain genes
render a patient
susceptible to a
disease
-patterns of
expression lead to
higher rates of
disease

-metaanalysis of 12
primary studies
-calculated OR and
CI for all studies
-overall found a high
and low frequency
gene related to lung
cancer

-Metaanalysis of 12
primary studies
-Is there a single gene
that show patient
susceptibility to lung
cancer?

Results

Critique

-significant increase
in risk of
developing DM-2
with certain genetic
markers of
dyslipidemia
-difficult to
estimate exactly
based on poor
mapping of some
genes coding for
lipids
-no single gene is
responsible for lung
cancer
-two highpenetrant, lowfrequency genes are
association with
development of
lung cancer

-large sample size
-well constructed
treatment and control
groups
-question the
comparison of US
and European
populations as
treatment/control
comparisons
-well done statistical
analysis
-calculated CI for
each study to add
strength to final
statement
-strict
inclusion/exclusion
criteria
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Articles
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Description of
Concept
-genes contribute
considerably to
disease
-protection from
and susceptibility
to disease are seen
-genes influence
MS susceptibility

Measurement/Study
Design
-n=1784
-cohort study, casecontrolled
-correlational
statistics looking at
MS and genetic
makeup
-convenience sample
of patients at 3
clinics with known
MS

Study
Purpose/Question
-Aim was to
investigate
association to
multiple sclerosis all
three classes of HLA
I genes

-susceptibility is
the strongest term
that can be applied
to genetic testing
-associations
between genetic
markers and
disease
-environment plays
a huge part in
disease

-none, narrative
review article

-To discuss the
association between
genes and diabetes

Results

Critique

-2 of the 3 HLA
classes predispose
patient to MS
-1 HLA gene
presence offers
protection from
development of MS

-poor/minimal
discussion section
-excellent description
of the problem
statement
-excellent statistical
analysis

-multiple genetic
markers are
associated with
IDDM
-not enough data to
determine distinct
predisposition
marker
-overlap between
IDDM and other
diseases in genetic
markers

-good overview of
the science of genetic
predisposition
-individual genetic
variation conferred
incomplete risk or
susceptibility to
disease
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Description of
Concept
-genetic
predisposition to
obesity has been
established
-physical activity
attenuates this
susceptibility based
on genetics
-environment,
activity, and
lifestyle play a
large role in
development of
disease

Measurement/Study
Design
-prospective,
population study
-n=20,000
-genotyped for 12
SNPs known to
increase BMI

Study
Purpose/Question
-Can the genetic
predisposition to
obesity be modified
by physical activity

Results

Critique

-those people with
genetic markers for
obesity can reduce
incidence of obesity
by 40% with
physical activity
-lifestyle
modification can be
powerful in altering
genetic
predisposition

-large, population
based study
-limited to the
European population,
not across all
populations
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Analysis of Concept
The question to be addressed in this analysis is: “What is the current state of the
science regarding the concept of genetic predisposition”? A principle-based concept
analysis method is employed to perform this analysis. The basis of the principle-based
concept analysis is evaluation of the concept in four key areas: epistemological,
pragmatic, linguistic, and logical.24 It is through these four principles that the concept
can be evaluated and the state of the science surrounding genetic predisposition as a
concept can be established. For the purposes of this analysis, the four undergirding
principles will be addressed individually and attention will be given to defining the
concept of genetic predisposition as a statement of the state of the science.
Epistemological
The epistemological principle refers to the nature of knowledge.24 When
examining the epistemological principle, a determination of the concept’s clarity and
differentiation from other concepts is analyzed. Genetic predisposition is not clearly
defined nor well differentiated from other concepts. Lack of clear definition is partly due
to the relatively immature nature of genetic predisposition.12 Literature can be grouped
into three overarching themes associated with the definition of genetic predisposition:
predictive, risk and susceptibility to disease. These three terms have different meanings
that are often based on the context in which they are discussed.
In order for a concept to be considered mature, it must be clearly positioned in the
body of literature.24 The concept of genetic predisposition is not well situated in the
literature and is not well-differentiated form other descriptions of risk or prediction. Lack
of the clear definition of genetic predisposition is based partly on a lack of understanding
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of the exact mechanisms of disease development and progression.16 Additionally, genetic
predisposition can be viewed in a negative connotation as in the risk of disease
development while other authors discuss genetic predisposition as being predictive of
health. 38,40,41 Because of the lack of clear definition, it is difficult to distinguish the
concept from others in the literature and is considered epistemologically immature.
Pragmatic
The pragmatic principle asks if the concept is useful and applicable in the
scientific community.24 To address this principle, the concept was analyzed from a
historical perspective looking longitudinally at the literature. As the concept of genetic
predisposition has evolved, the usefulness becomes increasingly apparent. Earlier work
on genetic predisposition was reluctant to make definitive claims about the usefulness of
genetics in predicting outcome.37 As the science of genetics has evolved and a greater
understanding of the human genome is realized, the usefulness of the concept of genetic
predisposition has been realized to help stratify risk, predict disease development, and
determine susceptible patients.15,29,42,43
Several studies have examined the utility of genetic predisposition to help predict
and stratify risk associated with disease development.15,31,34,39,44 Specific diseases include
colorectal cancer, breast cancer, and diabetes; all of which have been shown to have a
genetic component. This is useful to the practitioner to help stratify risk and plan
treatment along with suggestions for lifestyle modification to decrease risk.36 Also
emerging in the literature is the idea of genetic predisposition as a screening tool to be
useful at behavior modification. In this sense, genetic predisposition can be useful to
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help predict outcome from treatments or to determine lifestyle modifications to reduce
disease severity or development.
Linguistic
The linguistic principle asks if the concept is used consistently throughout the
literature with attention to the meaning of the concept.24 In this regard, genetic
predisposition has poor linguistic maturity. It is seen used to describe risk, predict
outcome, and determine susceptibility. The context in which the concept is used will
determine the meaning of genetic predisposition. For example, if examining the risk of
developing a disease, genetic predisposition has a negative connotation, as it is though to
be predictive of disease formation.36 Conversely, genetic predisposition can be seen to
represent hope when used to show how disease development can be halted or reversed
with lifestyle and environmental alterations.43,45,46
The concept of genetic predisposition has been applied in several contexts across
varying patient populations and environments. Although many studies focus on the use
of genetic predisposition in describing risk, there are other studies and review articles that
look at genetic predisposition to help stratify risk and determine susceptibility to disease.
Many terms and meanings can be seen used for the concept of genetic predisposition and
varying interpretations of these meanings makes the concept of genetic predisposition
linguistically immature.
Logical
The logical principle aims to determine if the concept of genetic predisposition
remains clear and holds its boundaries when integrated with other concepts.24 Because
the epistemological principle lacks clarity, there is an impact on the logical principle.24
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The analysis of the concept of genetic predisposition revealed that it is not well
differentiated in the literature so it cannot have clear boundaries compared with other
concepts. There are obvious overlaps between risk, prediction, and susceptibility all of
which make up genetic predisposition as a concept. This overlap creates ambiguity for
the concept and blurred boundaries when compared to similar concepts in the literature.
Limitations
Limitations to this concept analysis should be considered. The exclusion of
articles not in the English language limited the body of literature reviewed. Additionally,
the majority of articles selected were from medicine and genetics literature; there was a
paucity of literature in nursing, pharmacology, and the social sciences. Studies were
selected based on the inclusion criteria set forth above and no formal critique of the
quality of the studies was performed. Several of the included studies were review
articles, some with good methodological quality for searching and performing metaanalysis. Other review articles were integrative or narrative reviews and their findings
lack the weight of higher quality reviews. There were no identified systematic reviews
for inclusion.
Conclusion
The principle-based concept analysis of the concept of genetic predisposition has
revealed an immature, although developing concept. Genetic predisposition lacks
epistemological, linguistic, and logical maturity but does have pragmatic maturity and
usefulness. Based on this analysis, the concept of genetic predisposition can be defined
as the use of genetic testing to predict disease, stratify risk, identify susceptibility and
guide prevention of disease. Further research into the usefulness of genetic
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predisposition from the patient perspective would prove invaluable in advancing the
concept. Understanding the patient’s perception of genetic predisposition and applying
this understanding to planning care and screening tools would be beneficial.
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Chapter 3: Instruments to measure acute pain: An integrative review
Riddle, D. (2014). Published in Journal of Pain Management, 6(4). 273-280.21
Abstract
Context: Acute pain impacts approximately 45% of the world’s population and is a cause
of delayed discharge and increased cost to the healthcare system. If not appropriately
treated, acute pain can transition into chronic pain resulting in long-term complications.

Objectives: The objective of this integrative review is to synthesize and describe the
current instruments used to measure acute pain.

Methods: A systematic three-stage search strategy was used to review the literature.

Results: A total of 1754 manuscripts were identified with 8 meeting all inclusion criteria.
Many of the instruments report various aspects of psychometrics but only 5 report
reliability, validity, and address feasibility.

Conclusions: Caution should be exercised when using the currently available instruments
to measure acute pain. Since treatment decisions are often based solely on the pain
measurement instrument, it is important to ensure the chosen instrument is both reliable
and valid.

Key Words: acute pain, instrument, review, psychometrics, integrative review
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Introduction
Pain, as a concept, is an unpleasant or unwanted feeling often brought on by an
injury or illness.47 It is estimated that approximately 50% of the American population
suffers from some form of acute or chronic pain.6 Within the past few years, there has
been a push internationally to think of pain as the “Fifth Vital Sign” signifying its
importance to both the patient and healthcare provider.48 Physiological implications of
pain include: increased catecholamine release, changes in intrinsic cortisol levels, and
delayed wound healing as well as psychological problems like depression and anxiety
49,50

.
Pain is typically considered subjective, can be defined by the person experiencing

it and can be described in multiple different ways. Theoretically, pain is defined as an
aversive, uncomfortable, and unwanted sensation.51 To operationally define pain a score
or rating on a particular measurement scale is often used. Given the heterogeneity of
individual pain perceptions, the measurement of pain as a construct has been labeled
difficult to accurately measure.52
There are several defined types of pain including acute, chronic, and neuropathic
pain. The focus of this review is to critically review the clinically used instruments that
are aimed or focus on measuring acute pain. Acute pain is often defined as the normal
physiologic response to adverse physical stimulus such as trauma, surgery, and acute
illness.53 The patient’s self-reported pain score often predicates treatment of acute pain
and there are several instruments in use clinically that purport to measure pain. The
purpose of this integrative literature review is to synthesize the best available evidence
related to quantitative instruments used to measure acute pain.
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Theoretical Framework
Currently, several theories informing the study and pathophysiology of pain. As
proposed originally by Melzack and Wall, the gate control theory of pain proposes that
there is a natural physiologic factor (gate) that modulates pain impulses within the spinal
cord.54 When a noxious impulse is perceived, large nerve fibers inhibit the transmission
of some of the stimulus to the brain through afferent nerve tracts. The gate, or large
nerve fibers, are effectively closed at this point and stimulation of the dorsal horn neurons
of the spinal cord does not occur and the perception of pain is decreased.55
The gating mechanism is influenced by nerve transmission descending from the
brain and this mechanism is though to explain some aspects of normal physiologic
functioning in the face of pain.54 Factors influencing the gating mechanism include the
amount of activity of pain fibers, the presence of analgesic medications, and emotional
factors such as depression and mood.56 Although the gate control theory of pain does not
explain everything regarding pain, an in-depth study of this framework does explain why
various medications and treatment modalities are effective in controlling pain. Within the
current literature, the gate control theory of pain is one of the accepted frameworks.
Search Strategy
Using a three-step search strategy, the literature was queried to find relevant and
related studies. Consultation with a health science reference librarian was utilized to
hone and refine the search terms and databases. In the first step of the search, the key
words “measurement” and “pain” were used in the Cumulative Index to Nursing and
Allied Health (CINAHL) and MEDLINE databases to ascertain relevant articles and
additional key words related to the concept of interest. In the next step of the search
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strategy, all identified key words including acute pain, measurement, instrument, and
self-report were utilized across CINAHL, MEDLINE, PUBMED, and PsychINFO
databases. In the third step of the search, the reference list of all articles meeting
inclusion criteria was searched for additional manuscripts. Figure 1 represents the search
strategy and articles found with each step. Of note, one article was not found using a
database search; instead the article was shared by a colleague and is included as it meets
inclusion criteria.57 Overall, eight articles were utilized in this integrative review and
Table 1 represents the relevant findings from those articles.
For the purposes of this literature review, the focus was on instruments that are
self-reported measures of acute pain levels. Instruments that are designed for use in
sedated or cognitively impaired individuals were excluded. Additionally, as the focus of
this review was the adult population, studies related to instruments for use specifically in
children were also excluded. Lastly, only instruments that were available in the English
language were examined. There are several studies that address the psychometric
evaluation of instruments for application in other languages; these studies were excluded,
as no translational services are available. There was no date-limit set for this literature
search.
Results
Each of the 8 studies included in this literature review represents a self-reported
method of measurement of acute pain. Seven of the eight studies were conducted in the
United States and one was conducted in England. Overall, the quality of the studies was
fair with medium to low-level evidence informing these results.58 The combination of
these eight studies represents 1,278 total study participants. Only two of the eight studies
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reported a theoretical framework for their study design.59,60 Three of the eight studies
reported information on a newly developed scale aimed at measuring acute pain.57,59,61
The remaining five studies examined psychometric properties of existing instruments
with new applications or revised designs. Specific psychometric properties of the eight
included studies are reported in Table 1.
Reliability
Seven of the eight studies report some measure of reliability. In pain management
research, reliability is commonly measured in reliability coefficients, which is a measure
of stability and consistency over time.62 This is commonly reported as Cronbach’s alpha.
Six of the eight studies report reliability in terms of internal consistency with Cronbach’s
alpha scores. Consistently, the measures of internal consistency as represented by
Cronbach’s alpha are high (>0.95) across all six studies. The Visual Analog for Pain
study used Interclass Correlation Coefficient (ICC) scores between one-minute
measurements and the McGill Pain Questionnaire study performed three confirmatory
factor analysis models to test for reliability. 63,64
Validity
Seven of the eight studies report validity results with varying methods for
calculating and reporting validity. Two studies reported strong validity but did not
provide psychometric calculations to support this statement. The remaining five studies
reported validity primarily using factors analysis and are reporting convergent validity.
Where reported, various validity scores are strong but often-exact statistical measures are
not specifically reported in the manuscript.
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Discussion
This integrative review found eight unique scales that measure acute pain.
Previous reviews on pain instruments have been broad in scope and have not examined
pain instruments related specifically to acute pain; therefore, the included eight studies
represent only those instruments for which studies have examined psychometric
properties for measurement of acute pain. According to this literature review, the McGill
Pain Questionnaire and the Visual Analog Scale for Pain are the two most commonly
used pain instruments in the clinical setting.65
Strong reliability scores have been reported in most of the included studies;
psychometric scoring for validity is sparse. There are many studies that indicated the
instrument is valid but did not provide supporting evidence to the reader. As pain is a
subjective concept necessitating patient reported scores for quantification, the lack of
consistent validity scores raises concerns. As validity of a scale is foundationally a
measure of how well the instrument measures what it purports to measure, it is possible
that those instruments with no validity scores are not actually measuring pain but some
other construct.
Although reliability was shown to be strong across the entire included
instruments, the lack of consistent reporting of validity raises concern. This is especially
important when considering clinical implications of pain management. As a subjective
concept, pain can only be measured indirectly by asking the patient about his or her pain
levels. To measure pain, it is necessary to use an instrument to quantify the pain level,
which is individualized. Treatment decisions and patient care are planned based on the
reported pain levels. If an instrument is used that does not have adequate validity, there

	
  

33	
  

	
  
is a danger of reporting a score that is not a true representation of the construct being
measured. In this situation, potent and lethal medications could be administered and
inappropriate discharge planning, or incorrect pain management procedures could be
performed based on an erroneous pain score.
Additionally, many studies have shown that pain is far more complex than what is
represented by a single score.12,50 In measuring pain, this balance between a simple,
quick, and useful instrument and an instrument that is comprehensive enough to measure
the multiple facets of pain is difficult. This balance can be seen in this review by
examining 1-item instruments, like the PAULA scale, as compared to an instrument like
the MAPS scale that includes 101-items and requires considerable time to complete.60,66
The key to finding an appropriate and useful instrument to measure pain is finding an
instrument that is comprehensive enough to capture all of the facets of pain, short enough
not to be burdensome to the patient, and has applicability to a wide range of the
population.
One additional consideration that is not addressed in any of the studies is the
phenomenon of sedation related to pain treatment. Frequently, acute pain is treated with
medication that can cause sedation; sometimes this sedation can be profound. None of
the studies examined the feasibility of using the instrument with a patient who is being
actively treated for acute pain episodes. This raises concerns regarding the reliability of
the instrument across the spectrum of an episode of acute pain. A clinical example is the
patient in the immediate post-operative period receiving opioid analgesics for acute
surgical pain. Although important to measure pain in this particular population,
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reliability of the various available instruments has not been established in the face of a
sedated patient.
Further research aimed at establishing validity of the various instrument used to
measure acute pain is warranted. When clinical treatment decisions are based largely on
scores obtained from pain instruments, it is of paramount importance to ensure the
instruments are indeed measuring the construct of pain and not some other construct.
This is critically important given the untoward side effects of the most commonly used
treatment for acute pain: opioid analgesics.3 The side effect profile of opioid analgesics
can range from bothersome pruritus and constipation to severe respiratory depression and
respiratory arrest.67 Given the significant and dangerous side effects of the treatment of
acute pain, it is essential that the instruments used to measure the construct on which
treatment is based be reliable and valid for that construct.
Conclusion
There are several instruments available to measure the construct of pain. Of the
eight reviewed instruments, only five have reliability and validity that would warrant
clinical applicability. It is useful to have a varying and wide array of instruments that
will fit with various populations. It is incumbent on the person administering the
instrument, however, to make sure that it is reliable, valid, and applicable to the
population in question. Fortunately, several instruments with excellent validity and
reliability are feasible to use in measuring pain.
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Table 1. Data extraction and psychometric properties
Instrument
Reference

Framework

Sample
Subjects

Brief Pain
Inventory
Revised (BPIR): 68

Not reported

Adult surgical
cancer patients
at two VA
hospitals in the
US, n = 388

Brief Pain
Inventory
(BPI): 62

Not reported

Adults with
bone
metastases
receiving
palliative
radiotherapy
for acute bone
pain, n = 45

	
  

Instrument
Description
and Scoring
23-item selfreport with
response
categories of
0-10 ordinal
scale; higher
number
indicating
more intense
pain;
15 minutes to
complete
11-item
questionnaire
with response
categories 010 ordinal
scale with 0 =
no pain and 10
= worst pain
possible
including one
question
asking for list
of medications

Reliability

Validity

Feasibility

Level of
Evidence58

Cronbach’s
alpha = 0.95
for medical
patients
Cronbach’s
alpha = 0.97
for surgical
patients

Calculated by
comparing BPI
with VAS;
Pearson
correlation
coefficients =
0.70 for
medical
patients; 0.60
for surgical
patients

Reasonable,
only 15
minutes to
complete the
23-items; free
instrument to
use

2b

Cronbach’s
alpha = 0.950
for worst pain
scores; 0.939
for average
pain scores;
and 0.939 for
current pain
scores

Reported as
having strong
validity with
high
correlation
coefficients

Short, 11 item
questionnaire
applicable to
metastatic
cancer patient
with acute
bone pain

2b
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Instrument
Reference

Framework

Sample
Subjects

PAULA the
PAIN-METER
(PAULA): 66

Not reported

Adult patients
in the postanesthesia care
unit having
undergone
surgery, n = 65

Continuous
Pain Score
Meter (CPSM):

Bio-feedback

Healthy adult
volunteers,
mean age 30, n
= 32

59

	
  

Instrument
Description
and Scoring
Sliding ruler
designed to be
moved by the
patient
corresponding
to level of
perceived pain
with response
categories of 5
colored faces
representing
pain intensity

Reliability

Validity

Feasibility

Level of
Evidence58

Internal
consistency
Cronbach’s
alpha = 0.98

Not reported

Simple, slide
rule design but
only measures
one aspect of
pain.
One-item
instrument
might be at
risk for poor
content
validity.

2b

Electronic
instrument that
measures
continuously
the movement
of a slider
connected to a
computer with
a continuous
range response
varying from
0-10

Test-re-test
reliability
reported as
“excellent” but
no statistics
were given

Considered
valid by
authors, no
discussion of
testing for
validity

Required a
sophisticated
computer
software and
hardware
assembly; no
validity
reported

2b
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Instrument
Reference

Framework

Sample
Subjects

Multidimension
al Affect and
Pain Survey
(MAPS): 60

Frequency
pattern of
correlations

Oncology
patients at one
major medical
center with
various types
of cancer, n =
81

Defense and
Veterans Pain
Rating Scale
(DVPRS): 57

Not reported

Military
members
(active duty or
retired); n =
350

	
  

Instrument
Description
and Scoring
101 item
instrument
describing
pain and pain
symptoms and
patient rate
agreement
with descriptor
on a 0-5 point
scale; 0 = none
at all, 5 = very
much so
5-item VAS
plus PFS with
response
categories 010 with
0=none and
10=worst
combined with
4 supplemental
questions with
response
categories 010 indicating
degree of
agreement
with the
statement

Reliability

Validity

Feasibility

Level of
Evidence58

Not reported

Factor analysis
using pattern
analysis
approach

101 questions
is a significant
burden on the
respondent;
over 70
minutes was
required to
complete the
instrument;
difficult to
score

2b

Internal
consistency
reliability
Cronbach’s
alpha = 0.902

Principal
component
factor analysis
for construct
validity factor
loadings >0.82

8-9th grade
reading level;
easy to
administer and
quick to
answer, little
burden on the
participants,
unknown
about
availability
outside the
military
population;
useful in
clinical
research

1b
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Instrument
Reference

Framework

Visual Analog
Scale for Pain
(VAS): 63

McGill Pain
Questionnaire
(MPQ): 64

	
  

Sample
Subjects
Adult patients
in the
emergency
room of two
facilities, n =
96

Not reported

Adult patients
participating in
larger RCT in
VA medical
system; n =
221

Instrument
Description
and Scoring
1-item scale
with response
categories
continuous
along a
100mm line
representing a
continuum of
pain levels;
one end “least
possible pain”
other end
“worst
possible pain”
22-item pain
descriptors
including 4
summary
scales
assessing
continuous,
intermittent,
descriptors,
and affect with
a 0-10 rating
scale; 0=none,
1=worst
possible

Reliability

Validity

Feasibility

Level of
Evidence58

ICC were used
with 0.97 ICCs
between 1minute
measurements

Convergant
validity when
correlated with
NPS 0.95

Simple, 1-item
scale, usable
for those not
able to read,
universal in
language,
widely used;
useful in
clinical
research

1b

3 confirmatory
factor analysis
models used;
reliability for 3
models are r =
0.98; r = 0.88;
r = 0.86

Convergent
validity as
compared to
itself r = 0.74;
discriminant
validity
reported as
“excellent” but
without
statistics

Widely used
instrument that
requires only
10 minutes to
complete;
comprehensive
examination of
pain; limited
to English
speaking/readi
ng patients

1b
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Figure 1. Search Results
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Chapter 4: Clinical utility of pharmacogenomic testing among anesthesia providers:
A mixed-method study
Introduction
Pharmacogenomic testing is becoming more widely used to assist healthcare providers
make personalize healthcare decisions; however, a stark gap exists in the literature about the
perceived clinical utility of pharmacogenomic testing in supporting prescriptive decision-making
among practicing anesthesia providers. Pharmacogenomic testing can categorize how an
individual’s variation in deoxyribonucleic acid (DNA) will control drug metabolism by
programming how the cytochrome P-450 (CYP450) system for drug metabolism functions.5
With pharmacogenomic testing of an individual’s CYP450 system, the results can support an
anesthesia provider’s prescriptive decision-making and help minimize ‘guessing’ about which
drug and dose is best for the patient69. In the rapidly developing field of personalized medicine,
in which pharmacogenomics play an integral part, this technology is a key component of helping
an anesthesia provider determines which medications will work best for their patient.
Despite the advancement in pharmacogenomic testing technology and the supporting
interpretative software translating its results, the clinical uptake has been slow.1,5 Although
clinical outcomes studies demonstrate superior patient outcomes when pharmacologic decisions
are made based on genetic information, few studies demonstrate the perceived clinical utility of
pharmacogenomic technology in supporting prescriptive decision-making.6,69,70 Attitudes of
anesthesia providers towards pharmacogenomic testing and their perceptions of clinical utility of
the technology in supporting clinical decisions are currently unknown.
In the United States, there are multiple corporate entities that produce, market, and
promote pharmacogenomic testing technology and the supporting software for interpretation of
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the results. The myriad of differences in the complexity of the testing platforms, the availability
of the technology in real-world clinical practice settings, and the ability of the patient and the
anesthesia provider to interpret and apply the results in real-world clinical practice is unknown.
As the clinical utility of the pharmacogenomic testing among anesthesia providers is
currently unknown, this study aimed at describing how anesthesia providers in clinical practice
perceive the usefulness and support the uptake of pharmacogenomic testing as well as quantify
these perceptions. Additionally, results of previous work demonstrate that both qualitative and
quantitative measurement of provider perceptions of clinical utility is necessary before
advancement of technology into routine clinical practice can be successful.15 Similar work has
been conducted in the field of hepatology, nutrition, and primary care with feasibility of a mixedmethod approach to establishing clinical utility having been established in these previous
works.15,16,71 The purpose of this study, then, is to develop a survey based on qualitative
perceptions of anesthesia providers to better understand the perceived clinical utility of
pharmacogenomic testing related to clinical prescriptive decision-making.
Theoretical Framework
The guiding framework for this study is the Centers for Disease Control and Prevention’s
(CDC) ACCE Model of Public Health Genomics.22 The model’s dimensions include analytic
validity; clinical validity; clinical utility; and ethical, legal, and social implications of a genetic
test. The clinical utility portion, or outer ring, of the model was used to ground this mixedmethod study (Figure 1). Anesthesia providers were questioned about knowledge, education,
perceived barriers, and perceptions of how the technology could impact patient care.
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Figure 1. CDC ACCE Model of Public Health Genomics
Research Design and Methodology
This study was a sequential qualitative-quantitative mixed-method design that explored
the perceptions of anesthesia providers regarding the clinical utility of pharmacogenomic testing.
Participants were any licensed practicing anesthesia provider with unrestricted privileges to
provide direct patient care. Ten individuals were recruited to participate in the qualitative phase
of this study. Initially, qualitative semi-structured interviews were conducted with 10 practicing
anesthesia providers. Following analysis of the qualitative data, probes were developed based on
the themes that emerged from the qualitative interviews. These probes were then formulated into
a quantitative survey designed to quantify the perceptions of anesthesia providers about clinical
utility of pharmacogenomic testing.
The qualitative portion of the study utilized case-study methodology as originally
proposed by Yin.72 Using purposive sampling of 10 practicing anesthesia providers, semistructured interviews were conducted. Questions for the qualitative interview were developed
using the CDC ACCE Model of Public Health Genomics; Clinical Utility.22 Appendix 1 is the
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focused interview guide. Interviews were conducted in the anesthesia provider’s place of
business, usually in a private office or private consultation room. The primary investigator
conducted all interviews, which were audio recorded and transcribed using a professional
transcription service.
Following data analysis and thematic development of the qualitative data, probes for a
quantitative survey were developed from the qualitative data set results. Survey development
was based on the Office of Behavioral and Social Sciences and Research guidance on
development of surveys in the field of human subjects research.73 This survey was initially tested
with the original 10 participants from the qualitative portion of the study. This allowed for
triangulation of the data and revision of the initial survey instrument.73 Cognitive pretesting and
subsequent item revision were conducted. The final survey that was administered is attached as
Appendix 2. The survey was constructed and administered using the REDCap ™ system. The
sample for the quantitative survey was obtained from the American Association of Nurse
Anesthetists (AANA) and consisted of a random sample of 3000 practicing Certified Registered
Nurse Anesthetists (CRNA) in the United States and military instillations worldwide.74 The
survey was distributed electronically, in a blinded fashion, and the respondents could answer on
a computer, smartphone, or tablet device.
Data Analysis
Qualitative data analysis was conducted using case-study methodology as proposed by
Yin and colleagues.72 Following professional transcription, the individual interview transcripts
were validated for quality by the primary investigator. Using multiple-embedded case study
methodology, each provider was assumed to represent an individual case. Each anesthesia
provider represents an individual case because they each care for a cadre of patients; their
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individual practice represents the sum of the care provided for the cadre of individuals receiving
an intervention.72,75 Yin indicates that for case-study methodology exploring new concepts, only
a minimum number of subjects are necessary to achieve data saturation.
Using NVivo® qualitative data analysis software, data were first deductively coded,
framed by the CDC ACCE Model of Clinical Utility.22 Using cross-case synthesis methods, each
anesthesia provider was treated as a separate case and embedded cases were established after the
first case was coded. Following deductive coding, inductive coding using constant comparison
was used to develop key themes in the entire data set.76 The process used to establish rigor of the
findings was based on a systematic process of coding and interpretation.77 In this process, the
primary investigator initially reviewed and coded the data based on the ACCE Model. Next, a
second, expert qualitative researcher coded the data using the same method. Systematic
comparison was made between the primary investigator and the expert methodologist to compare
findings, negotiate consensus, and ensure rigor of the coding and analysis process.77
Following qualitative data analysis, the themes that emerged were used to formulate
survey items aimed at quantifying provider perceptions of clinical utility. Initially, questions
were constructed based upon each theme that emerged and those questions underwent cognitive
pretesting with the group of 10 original participants. Refinement of the questions was then
conducted. Each question consisted of a unidirectional, Likert-scale type question that aimed to
measure only one distinct concept. Two items were constructed per theme for a total of 14-items
on the final survey.
Factor analysis using the maximum likelihood extraction was used to analyze the data.78
This method allows for inferences to be made on the population as a whole based on the
extracted factors from the sample, which is appropriate for this quantitative data.79,80 Because
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the factor analysis is exploratory and descriptive, an assumption of the maximum likelihood
method that each item have a normal distribution was relaxed. To determine the strength of
relationship among items as a measure of sampling adequacy the Kaiser-Meyer-Olkin test was
used to evaluate whether the numbers of significant correlations were sufficient for factor
analysis.79 Criteria for extraction included visual examination of the Scree plot and as a
secondary measure, Kaiser’s criteria recommending retention of factors with eigenvalues greater
than 1.79 To facilitate factor interpretation, factors were rotated using the Direct Oblimin
technique, which is useful when factors are thought to be related. Following maximum
likelihood extraction, Horn’s parallel analysis was carried out to confirm the number of factors
extracted sufficiently loaded and that minimal residual remained. Data were analyzed using IBM
SPSS version 22 for Mac (IBM Corp, Armonk, New York).
Qualitative Results
Deductive coding was conducted first. Framed by the CDC ACCE Model of Public
Health Genomics, five themes emerged from the analyzed data set. These themes were: a lack of
understanding and knowledge about the technology, a lack of facilities to conduct and interpret
the testing, limited access to the technology, economic concerns about genetic testing, and finally
legal and ethical implications of ordering genetic testing.
The first theme that emerged from the data centered on understanding and knowledge
about pharmacogenomic testing and the interpretation of the results related to clinical decisions.
Providers indicated they did not have enough education as it relates to pharmacogenomic testing
to see it as useful in their anesthesia practice:
“Well, I'm not really sure how it would impact the patients because I don't yet know the
value of it, I don't know enough about it.”
“We're gaining knowledge that may have utility once we understand it better”
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Further, providers indicated they lacked facilities to conduct and interpret the findings of
pharmacogenomic testing. Most providers indicated that they did not have access to ordering the
pharmacogenomic test in their facility of practice nor did they know how to order the test if it
was available. In answering the question regarding impactfulness of the technology, providers
indicated they were limited at times in their access to the technology:
“I guess coming from a rural-type facility and practice, we're limited a lot of times in
things that are available to us. We may not have a big variety of medications to choose
from. We tend to be pretty limited to what we have and so, in some ways, it may not
influence what we do.”

	
  

“Currently I'm in a small facility and in a rural facility and it seems like, with medicine,
that technology is usually centered around the big facilities where they've got the money
and they've got the ability to study those technologies”
Anesthesia providers universally were concerned about the economic implications of

pharmacogenomic testing. Concerns related to the actual cost to the patient, cost to the healthcare
system as a whole, and costs to the provider if the third-party payers do not cover the testing
expense were all prominent in the data. Additionally, providers thought that there is probably
not a good cost-benefit ratio that is currently available to support the use of pharmacogenomic
testing in their practice:
“Did I really need to do an expensive test to figure that out? Or, can I just write a
prescription and if they responded really well to it, okay, break in half-- take a half one,
instead. Or, "Wow, that isn't strong enough for you? Okay, well, you have to take two
instead of one." I didn't need a multi-thousand dollar test to figure that out”
“I think actual barriers may be to some degree the expense of it as it's being developed. I
think any new technology is usually pretty expensive, until it has been in use for a longer
period of time. I think that that's the main problem, is going to be money”
“I think instituting the technology is going to be somewhat slow. I think people are really
resistant to changing things in the first place. It's expensive, I'm sure, to develop this
technology, and I think that those kinds of things can make an adoption of a technology
like that somewhat difficult”
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“If the technology advances, it will have to come to a point where it became affordable
which takes time and then it may have an impact on rural facilities.”
Anesthesia providers did seem to think that pharmacogenomic testing might be
advantageous which speaks to the effective benefit of the ACCE Model. Participants expressed
the results of pharmacogenomic testing could be useful to plan their anesthetic care. They
expressed pharmacogenomic testing would result in less pain, faster recovery times, and provide
a better, more patient-centered way of delivering anesthesia care. Providers indicated they think
the technology would help to focus care, inform decisions, and have positive impacts on patient
outcomes.
“I think the advantages to the technology is being able to narrow down with our patients
what is the best drug to be used for them - the amounts of the drug. So, that we can target
our patient population to tailor the best anesthetic for them”
“If you could really tailor your anesthetic to that patient then obviously you're going to
wake up faster, you're going to wake up crisper, you're going to wake up the patient more
alert, less pain and all the side effects that go along with what we do in the OR so that
they would have a better experience with that”
The final theme that emerged from the deductive analysis of the data focused on the
ethical, legal, and social implications of using pharmacogenomic testing to help inform clinical
decisions. Providers generally expressed that there was perhaps an increased liability or
exposure to risk if they ordered and used a genetic test in practice:
“I think if I do the test and it shows, on one side, they might be have a very high addictive
potential and I decide to prescribe anyway, that might increase my liability. Because, I
knew ahead of time this was going to be a problem. On the other side, if it shows that
they were a high metabolizer and they would require high doses of opioid, and so, I used
that to drive my prescribing practices, in that I would write higher doses for them right
off the bat. And, they either had an adverse event based on the higher dose that I gave
them, and/or they were diverting and I just thought, Oh well, I misinterpreted that
information as they are high metabolizers, so, I'm just going to have to keep on giving
them more and more medications. I think that might be misleading or a false sense of
security.”
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Following the deductive coding, inductive coding was undertaken using constant
comparison methods. The first theme that emerged from the inductive coding was the
complexity of the technology. Providers general thought that the pharmacogenomic testing was
extremely complex and difficult to understand. They indicated not only was the technology
complex in interpretation, but understanding when it was indicated an how to go about ordering a
test, as well as developing their personal comfort in using the test in clinical practice was all very
confusing:
“All of the details of that are very confusing to me. It's not something I am comfortable
with and it's almost to the extent that I perceive the interpretation of the test as something
that would be so burdensome that I wouldn't want to do it.”
“I think, from my perception, is that we have a test that may or may not be a really
powerful tool. And, the deal is that they've got a billing code for it, but there is not a lot
of research out there to show us if you do this test in this scenario it can improve your
outcomes in this fashion.”
The final theme was the providers’ feelings that using the pharmacogenomic testing to
support decision-making would help them avoid complications in the care of their patients.
Providers felt that they could use the technology to narrow and focus their care and make
decisions about the very best care possible; not just the status quo. Additionally, they felt that
knowledge was power and the more information you know ahead of the proposed anesthetic the
better the care delivered:
“My initial inclination would be that if you've got insight into the genetics of a person
that that would dictate decisions that you make for them, along the lines of malignant
hyperthermia or something like that. The more you know about the makeup of the person,
the better able you are to choose appropriate medications.”
“I think the advantages to the technology is being able to narrow down with our patients
what is the best drug to be used for them - the amounts of the drug. So, that we can target
our patient population to tailor the best anesthetic for them”
“Less post-operative nausea, and vomiting, etc. Those kinds of things. Less postoperative pain. I really think that that has a whole lot of promise for patients.”
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Quantitative Analysis
Following analysis of the qualitative data, seven themes emerged as concerns anesthesia
providers had regarding pharmacogenomic testing. To accomplish factor analysis of the
proposed instrument, two items were constructed per construct to be measured. The primary
investigator developed the 14-item survey and cognitive pre-testing of the survey was
accomplished with all ten of the qualitative participants. These qualitative participants practiced
in community hospitals, rural hospitals, outpatient settings, and academic medical centers. Their
years of experience ranged from six to 27 and all were actively practicing anesthesia providers.
Following refinement of the survey instrument, it was formatted into the REDCap ™ survey
management system. Survey items consisted of 14 items on a 0-10 Likert scale with 0 meaning
completely disagree and 10 meaning completely agree. All items were written with
unidirectionality.
A random sample of 6,000 practicing Certified Registered Nurse Anesthetists in the
United States and military instillations worldwide were invited to participate in the electronic
survey. Through the AANA research division, a random list of potential participants was
formulated. This list was generated from the database of CRNAs and filters were applied to only
sample actively practicing CRNAs.

An invitation letter was electronically distributed to

participants explaining the purpose of the survey and inviting participation. An electronic link
was included in the letter directing potential participants to the electronic survey system. A total
of 325 surveys were returned representing a 5% response rate.
Construct validity was assessed by factor analysis. A total of 262 complete surveys were
used in the analysis and cases were excluded list wise if they had any missing variable responses.
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Results
Participant characteristics
The age of the participants was a mean of 48 +/- 11 years. There were 44% male and
52% female respondents. Seventy eight percent of the respondents did not identify a practicing
specialization while 1% indicated they specialized in neuro anesthesia, 4% in obstetrical
anesthesia, and 5% in pediatric anesthesia. Fifty four percent of respondents indicated they
practiced in a community hospital, 25% in an academic medical center, and 15% in outpatient
settings. Seventy two percent of the respondents reported a Master’s degree as their highest
earned degree with 12% Bachelor’s, 8% Doctorate, and 6% Certificate-prepared. Participant
characteristics are presented in Table 1.
Table 1. Participant characteristics.
Age (years)
Gender (% male)
Practice location (%)
-community hospital
-academic medical center
-outpatient facility
Practice type (%)
-not specialized
-pediatrics
-OB
-neuro
Degree (%)
-Certificate
-Bachelor’s
-Master’s
-Doctorate

48 +/- 11
44
54
25
15
78
5
4
1
6
12
72
8

Factor Analysis
The Kaiser-Meyer-Olkin test (KMO), an overall measure of sampling adequacy, had a
value of 0.850 which indicated the patterns of correlations were relatively compact and sufficient
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to reveal distinct and reliable factors.79 Factor analysis resulted in three factors. Following
maximum likelihood extraction, Horn’s parallel analysis was carried out to confirm the number
of factors extracted. Parallel analysis confirmed that three factors sufficiently loaded and
minimal residual remained. Following analyses, the pattern matrix was examined to determine
the unique contribution of each item to each factor. Total variance is presented in Table 2 and
items that loaded on each factor are presented in Table 3.
Table 2. Total variance explained

The pattern matrix was examined to examine the unique contributions to each factor.
Items that loaded on each factor are presented in Table 3.
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Table 3. Rotated factor loadings
Items
Factor 1 (benefit)
Factor 2 (knowledge) Factor 3 (concerns)
Tailored care
.879
Quicker wakeup &
.808
less pain
Reduce adverse drug
.741
events
Perceived benefit
.467
Comfort with testing
.803
Enough knowledge to
.753
use
Specific training on
.576
testing
Way to order
.498
Easy to use
.462
Location uses testing
.439
Cost prohibitive
.932
Cost is reason not
.629
used
Testing means more
.496
liability
Ethical concerns
.400
about testing
Maximum likelihood extraction pattern matrix with Oblimin rotation. Only related items with
loadings greater than 0.4 are shown.
Factor 1 was labeled “benefit” because items related to the perceived “benefit” of the
pharmacogenomic test loaded on this factor. Factor 2 was labeled “knowledge” because items
related to understanding the technology and interpretation of the test results loaded on this factor.
Factor 3 was labeled “concerns” because items related to liability, cost, and ethical
considerations of pharmacogenomic testing loaded on this factor. The means for the scores for
each item that loaded onto each factor are presented in Table 4.
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Table 4. Means (standard deviation) of items loaded onto each factor.
Item
Factor One (Benefit)
Pharmacogenomic testing would allow me to tailor my anesthetic to
my patients
If I used pharmacogenomic testing, my patients would wake up
quicker and in less pain.
By using pharmacogenomic testing, I would reduce adverse drug
events.
I know how pharmacogenomic testing would benefit my patients.
Factor Two (knowledge)
I am confortable interpreting the results of a pharmacogenomic test
I have enough knowledge to use pharmacogenomic testing to help
me make clinical decisions
I have received some form of training in the use of
pharmacogenomic testing as it relates to making clinical decisions
In my primary practice location, I have access to or can order
pharmacogenomic testing
Pharmacogenomic testing easy to use an interpret
My primary practice location uses pharmacogenomic testing to help
providers make clinical decisions
Factor Three (concerns)
Pharmacogenomic testing is cost prohibitive
The reason pharmacogenomic testing is not widely used is cost
If I use pharmacogenomic testing in my practice, I am taking on
additional liability
I have concerns about the ethical aspects of pharmacogenomic
testing

Mean (Standard deviation)
4.6 (3.3)
3.4 (2.9)
4.4 (3.3)
3.9 (3.0)
1.2 (2.1)
1.2 (2.1)
1.6 (2.4)
0.6 (1.4)
2.1 (2.4)
0.7 (1.5)
4.1 (3.1)
4.2 (3.4)
2.8 (2.9)
2.8 (2.9)

Discussion and Conclusions
The use of pharmacogenomic technology to support prescriptive decision-making among
anesthesia providers has not been established. Qualitative data shows providers expressed they
lack the knowledge necessary to use pharmacogenomic testing in clinical practice. Also, these
providers expressed that cost and ethical/legal implications of pharmacogenomic testing might
prohibit them from incorporating this modality in their anesthesia practice. Anesthesia providers
expressed that the technology is complex and extremely difficult to understand; further, they
often do not have access to the technology or the ability to order the test in the place of practice.
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Anesthesia providers indicated that pharmacogenomic testing is promising and using it
could result in better, more patient-centered anesthesia care. This is an interesting finding, as the
anesthesia provider seems to understand the basic premise behind pharmacogenomics; however,
they have stated they lack the knowledge necessary to actually use and interpret the findings of a
pharmacogenomic test. Providers generally indicated that more personalized prescriptive
decisions could be made, especially for acute pain and nausea prevention, if pharmacogenomic
testing is used in anesthesia practice. Along with providing more personalized care, anesthesia
providers do indicate that pharmacogenomic testing would help to reduce adverse drug events
and overall help to reduce poor outcomes in clinical practice.
Results of the factor analysis of the quantitative survey show that anesthesia providers’
use of pharmacogenomic testing can help to be explained by three phenomena: lack of
knowledge, economic and ethical/legal concerns, and perceived or anticipated benefit to the
patient. Items from a 14-item survey can be effectively reduced to fewer items that would
directly question these 3 phenomena.
Limitations exist in this study. First, the qualitative interviews were conducted with
anesthesia providers that were geographically located in one region of North Texas. These
interviews and their resulting data do not represent the anesthesia population as a whole.
Although saturation was reached in the qualitative analysis, additional interviews could have
shown additional themes and feelings about pharmacogenomic testing. Second, a very small
response rate on the quantitative survey could have biased the results. The title of the survey
might have dissuaded individuals from responding, as pharmacogenomics is a foreign concept to
many practicing anesthesia providers.
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Future work should include analysis of the results of each item in the survey along with
correlational analyses to help determine if there are predictive factors that might play into an
individual provider’s perceptions and knowledge about pharmacogenomic testing (such as age,
degree, practice location).
Importantly, from this study, it was discovered that anesthesia providers need additional
education about pharmacogenomic testing. Providers are unaware of the rather minimal cost of
the testing and the wide availability of testing through various commercial entities. Providers are
also unaware of the specific outcome studies that demonstrate superiority in pain control and
antiemetic therapy when pharmacogenomic testing is used to guide prescriptive decisionmaking. Additional education in the areas ethical and legal implications of pharmacogenomic
testing as compared to a wider, more generalized genetic panel is needed. Interventions aimed at
helping anesthesia providers understand pharmacogenomic testing, it’s utility, use, and cost is
necessary.
Funding:
This study was supported by an unrestricted grant from the Texas Christian University
School of Nurse Anesthesia. Funding for the REDCap ™ system was provided by SCTR –
Office of Biomedical Services award number NIH/NCATS UL1TR000062.
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Chapter 5: Summary and Conclusions
Synthesis
The three manuscripts of this dissertation explore the field of genetics and genetic testing
as it relates to clinical practice. The literature has demonstrated that the era of personalized
medicine is here and healthcare providers need to embrace the field of genetics as part of a
comprehensive approach to providing healthcare. Despite the myriad of outcomes studies
demonstrating how genetics and genetic testing can improve care, it remains a relatively foreign
idea to most clinicians.
An analysis of the concept of genetic predisposition (Chapter 2) shows that it remains a
relatively immature concept. The concept is seen differently by different groups of people which
seems to indicate we are all “speaking a different language” when it comes to talking about
genetics. Genetics can represent hope and insight to some while is represents risk and threats to
others. To healthcare providers, the concept of genetic predisposition overlaps with other
diagnostic and prognostic testing modalities in stratifying risk, determining treatment, and
offering statistical insight for patients when speak about disease prognosis. The concept of
genetics as predictive is not extremely clear in the literature and this research identifies the need
to further clarify the concept of genetic predisposition for the patient and the healthcare provider
alike.
In relation to this dissertation, the concept analysis of genetic predisposition demonstrates
that the concept has no meaning to the anesthesia provider. Chapter 2 demonstrates a complete
lack of literature in the area of anesthesia providers and understanding of genetic predisposition.
Chapter 2 helps to define the research question as it relates to understand the concept of
pharmacogenomic testing (one aspect of genetic predisposition) among anesthesia providers.
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The concept of genetic predisposition, as it relates to helping predict drug responsiveness, is
lacking in context, maturity, and formality among anesthesia providers.
In order to know if a treatment, therapy, or intervention is helpful, it is necessary to have
psychometrically sound instruments to measure outcomes. The second manuscript (Chapter 3) is
an integrative review of the literature about instruments to measure acute pain. This review
identifies that pain is very difficult to measure because it is completely subjective. Furthermore,
it was demonstrated that pain is multifactorial in nature and there is not one single physiological
or biomarker that help to identify pain. This review does demonstrate that there are several
instruments in current clinical use that have strong psychometric properties to measure acute
pain. As anesthesia provider consider the use of pharmacogenomic testing to help make
decisions regarding pain therapy, the need to psychometrically sound, clinically useful
instruments to measure outcomes is critical.
The third manuscript (Chapter 4) of this dissertation explores the perceived clinical utility
of pharmacogenomic testing to support clinical decision making among anesthesia providers.
This mixed-method, sequential qualitative quantitative study used case study methodology to
explore the perceptions of 10 anesthesia providers of pharmacogenomic testing. Using focused
semi-structured interviews and multiple embedded case study analysis, it was determined that
seven themes resonate with anesthesia providers related to pharmacogenomic testing. Using this
foundational data, a quantitative survey was constructed to begin to develop a quantitative
method of measuring perceived clinical utility of pharmacogenomic testing. This survey was
electronically distributed and analysis was conducted using factor analysis.
The third manuscript helps to fill the gap in the literature that exists regarding anesthesia
provider perceptions of pharmacogenomic testing. Results of this study shoe that anesthesia

	
  

59	
  

	
  
providers have a lack of knowledge about how and when to use pharmacogenomic testing.
Additionally, anesthesia providers have concerns about the ethical and legal implications of
using genetic testing to help predict drug responses. Although anesthesia providers were shown
to perceive benefits in using pharmacogenomic testing, their lack of knowledge about it’s use
and concerns about ethics and economics severely limits it’s clinical utility.
The limitations of this dissertation involve the limited and focused population. As
preliminary data concerning anesthesia providers only, inferences to other members of the
healthcare community cannot be made. Additionally, this data is only preliminary and should be
considered as pilot data. Further refinement of the proposed instrument is necessary to more
precisely measure clinical utility of pharmacogenomic testing among anesthesia providers.
Future directions include the development of a more robust instrument designed to measure
clinical utility of pharmacogenomic testing among anesthesia providers. Also, the development
of an intervention aimed at increasing anesthesia provider knowledge about pharmacogenomic
testing is necessary.
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Appendix 1: Focused Interview Guide:
1. What do you perceive as the advantages to this technology?
2. What do you perceive as potential or actual barriers to this technology?
3. How would this technology impact your patients?
4. How would this technology impact your practice?
5. In what ways are/would you anticipate using this technology in your practice?
6. What other information would you like to share about your potential use of this
technology?
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Appendix 2. Survey instrument.
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